COMMUNIQUÉS West-GlobeNewswire

BridgeBio to Present Additional Open-label Extension Data from ATTRibute-CM at ESC Congress 2025
25/08/2025
PALO ALTO, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that one [...]
Propanc Biopharma Provides Shareholder Update
25/08/2025
MELBOURNE, Australia, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from [...]
MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases
25/08/2025
Acquisition expected to diversify and accelerate double-digit revenue growth with FUROSCIX ® , an innovative treatment for edema due to chronic heart failure and chronic kidney disease, addressing significant unmet need [...]
Incyclix Bio Secures $11.25 Million Series B Extension to Advance the Phase 1/2 Clinical Trial of INX-315 in Patients with CDK4/6 Inhibitor Resistant ER+/HER2- Breast Cancer or CCNE1-Amplified Solid Tumors
25/08/2025
Financing will enable the completion of the ongoing Phase 1/2 clinical trial of INX-315 in patients with recurrent advanced/metastatic cancer RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Incyclix Bio [...]
Jade Biosciences to Participate in Upcoming Conferences
25/08/2025
SAN FRANCISCO and VANCOUVER, British Columbia, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune [...]
EDAP to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
25/08/2025
AUSTIN, Texas, August 25, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to participate [...]
Climb Bio to Present at Upcoming September 2025 Investor Conferences
25/08/2025
WELLESLEY HILLS, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that members of its [...]
Sionna Therapeutics Announces First Subjects Dosed in Phase 1 Trial Evaluating NBD1 Stabilizer, SION-451, in Proprietary Dual Combinations in Development for the Treatment of Cystic Fibrosis
25/08/2025
Dosing initiated for SION-451 combined with SION-2222 and SION-451 combined with SION-109 in healthy volunteers; topline data anticipated in mid-2026 WALTHAM, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics [...]
Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress
25/08/2025
– 3-year data from open-label extension (OLE) studies demonstrate the potential for disease modification with durable seizure reductions and improvements in cognition and behavior on top of standard anti-seizure [...]
New Burnbox Updates to the 72-Hour Fasting Kit to Improve Your Experience
25/08/2025
VILNIUS, Lithuania, Aug. 25, 2025 (GLOBE NEWSWIRE) -- The 72-Hour Fasting Kit quickly became a favorite for its gut health benefits and weight loss support using science-backed products - but some users reported [...]
Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D., Ph.D., World-Renowned Neuro-Ophthalmology and Retina Experts, as Chief Medical Advisors
25/08/2025
Mark Kupersmith, M.D. appointed as Chief Medical Advisor, Neuro-Ophthalmology, following positive Phase 2 ACUITY trial results with Privosegtor (OCS-05) in acute optic neuritis and initiation of multiple programs in [...]
Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D., Ph.D., World-Renowned Neuro-Ophthalmology and Retina Experts, as Chief Medical Advisors
25/08/2025
ZUG, Switzerland, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Mark Kupersmith, M.D. appointed as Chief Medical Advisor, Neuro-Ophthalmology, following positive Phase 2 ACUITY trial results with Privosegtor (OCS-05) in acute optic [...]
Vaxxas secures ~A$90 million in funding to commercialise needle-free vaccination delivery technology
25/08/2025
Total equity and debt raising of ~$90 million provides runway to 2H 2027 Strong support from existing and new investors including SPRIM Global Investments Funds will be used to scale-up production of needle-free [...]
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI® (lecanemab)
25/08/2025
TOKYO and CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: [...]
Valneva Announces FDA’s Decision to Suspend License of Chikungunya Vaccine IXCHIQ® in the U.S.
25/08/2025
Saint Herblain (France), August 25, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the United States Food and Drug Administration (FDA) has suspended the license [...]
Valneva annonce la décision de la FDA de suspendre la licence d’IXCHIQ® aux États-Unis
25/08/2025
Saint Herblain (France), le 25 août, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé aujourd’hui que l’agence de santé américaine Food and Drug Administration (FDA [...]
argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG
25/08/2025
Study met primary endpoint (p-value=0.0068) First global phase 3 study to demonstrate clinically meaningful improvements in disease activity across all three subtypes – MuSK+, LRP4+, triple seronegative Supplemental [...]
OSE Immunotherapeutics Proposes Governance Evolution and Reaffirms Strategic Priorities ahead of Annual General Meeting
25/08/2025
OSE Immunotherapeutics Proposes Governance Evolution and Reaffirms Strategic Priorities ahead of Annual General Meeting New Board Structure Reflects Balanced and Proportionate Shareholder Representation New Governance [...]
OSE Immunotherapeutics Propose une Evolution de sa Gouvernance et Réaffirme ses Priorités Stratégiques à l’Approche de son Assemblée Générale Annuelle
25/08/2025
OSE Immunotherapeutics Propose une Evolution de sa Gouvernance et Réaffirme ses Priorités Stratégiques à l’Approche de son Assemblée Générale Annuelle Une nouvelle structure du Conseil qui reflète une représentation [...]

Pages